Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Centocor Remicade Two-Year X-Ray Progression Data To Be Ready For Cmte.

Executive Summary

Centocor will have two-year x-ray data on Remicade in the prevention of rheumatoid arthritis progression available for review at the upcoming meeting of FDA's Arthritis Drugs Advisory Committee.

You may also be interested in...

Enbrel Promotions May Use AUC Data, Erosion Scores, Not Superiority Claims

Immunex' Enbrel promotions may use data on percentages of patients with no increase in erosion scores and area under the curve data, but may not use the data to make superiority claims to methotrexate, the approval letter for a new indication for Enbrel states.

Arava/Methotrexate Combo May Expand Indication To Refractory Patients

A planned combination trial of Hoechst Marion Roussel's Arava and methotrexate in rheumatoid arthritis may justify expanding the use of leflunomide to patients not adequately controlled by methotrexate alone, HMR consultant Marc Hochberg, MD, University of Maryland, told the Arthritis Advisory Committee Aug. 7.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts